Invention Grant
- Patent Title: Expression of FOXP3 in edited CD34+ cells
-
Application No.: US16981223Application Date: 2019-04-25
-
Publication No.: US11713459B2Publication Date: 2023-08-01
- Inventor: David J. Rawlings , Iram F. Khan , Yuchi Chiang Honaker , Swati Singh , Karen Sommer , Andrew M. Scharenberg
- Applicant: Seattle Children's Hospital
- Applicant Address: US WA Seattle
- Assignee: SEATTLE CHILDREN'S HOSPITAL
- Current Assignee: SEATTLE CHILDREN'S HOSPITAL
- Current Assignee Address: US WA Seattle
- Agency: Knobbe, Martens, Olson & Bear LLP
- International Application: PCT/US2019/029082 2019.04.25
- International Announcement: WO2019/210042A 2019.10.31
- Date entered country: 2020-09-15
- Main IPC: C12N15/87
- IPC: C12N15/87 ; C12N15/00 ; C07H21/04 ; A61K48/00 ; C12N15/113 ; C12N9/22 ; A61K35/15 ; C12N5/0783 ; A01K67/00

Abstract:
Aspects of the invention described herein concern the incorporation of a FOXP3 cDNA (e.g., full-length human codon-optimized cDNA) into a FOXP3 gene or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human CD34+ cells or cells derived from edited CD34+ cells. In some embodiments, guide RNA sequences that are directed to FOXP3, AAVS1, or other candidate loci are used for CRISPR/Cas9-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided.
Public/Granted literature
- US20210054376A1 EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS Public/Granted day:2021-02-25
Information query
IPC分类: